The Comparison of Desfonak with Desferal in Patients with Beta Thalassemia Major: A Randomized Crossover Clinical Trial


Beta thalassemia (β-thalassemia) is one of the most common genetic disorders that reduces the amount of specific chain production in hemoglobin. The aim of this study was to compare the efficacy and safety of Desfonak with Desferal in patients with β-thalassemia major in Iran. 


and Methods The study was a two-treatment and two-period crossover Randomizedclinical trialdesign that was carried out on 100 thalassemic patients referred to Mohammad Kermanshahi hospital of Kermanshah city, Iran in 2018-19. Eligible patients were divided into two groups using a random number table (Group A, n=50; Group B, n=50). The group A received Desferal then Desfonak vs. (30 mg/kg in 8 h and 6 days in a week). The group B received Desfonak then Desferal. The data collection tool was a checklist, including variables of age, sex, AST, ALT, ferritin, urea, creatinine and different complications of gastrointestinal, articular, skin, respiratory system and hearing problems. The data were analyzed by STATA software (version 14.0).


The results of the study showed that there are no significant statistical differences between Desferal and Desfonakin terms of different complications of GI, articular, skin, respiratory and hearing systems (P>0.05). Also, the results showed that there was no significant statistical difference between Desferal and Desfonak in terms of variables of AST, ALT, ferritin, urea and creatinine at two time periods (P>0.05).


The results of this study highlighted that Desfonak and Desferal have similar efficacy and safety in patients with thalassemia major.

Article Type:
Research/Original Article
International Journal of Pediatrics, Volume:7 Issue:70, 2019
10195 - 10204  
روش‌های دسترسی به متن این مطلب
اشتراک شخصی
در سایت عضو شوید و هزینه اشتراک یک‌ساله سایت به مبلغ 300,000ريال را پرداخت کنید. همزمان با برقراری دوره اشتراک بسته دانلود 100 مطلب نیز برای شما فعال خواهد شد!
اشتراک سازمانی
به کتابخانه دانشگاه یا محل کار خود پیشنهاد کنید تا اشتراک سازمانی این پایگاه را برای دسترسی همه کاربران به متن مطالب خریداری نمایند!